<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="141018">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01265173</url>
  </required_header>
  <id_info>
    <org_study_id>CCCCSBP</org_study_id>
    <nct_id>NCT01265173</nct_id>
  </id_info>
  <brief_title>Comparison of Efficacy of Cefotaxime, Ceftriaxone, and Ciprofloxacin for the Treatment of Spontaneous Bacterial Peritonitis in Patients With Liver Cirrhosis</brief_title>
  <official_title>Comparison of Efficacy of Cefotaxime, Ceftriaxone, and Ciprofloxacin for the Treatment of Spontaneous Bacterial Peritonitis in Patients With Liver Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Spontaneous bacterial peritonitis (SBP) is one of the most serious complications of liver
      cirrhosis. Mainstay of treatment for SBP is use of proper antibiotics. Although, several
      antibiotics including cefotaxime, ceftriaxone, or ciprofloxacin are being used, it is
      unclear which drug is most effective. Our aim of study is to compare the efficacy of the
      three current antibiotics for the treatment of SBP in patients with liver cirrhosis.

      The primary hypothesis is that the efficacy of all the antibiotics will not significantly
      different. This is non-inferiority trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Spontaneous bacterial peritonitis (SBP) is one of the most serious complications of liver
      cirrhosis. Mainstay of treatment for SBP is use of proper antibiotics. Although, several
      antibiotics including cefotaxime, ceftriaxone, or ciprofloxacin are being used, it is
      unclear which drug is most effective. Our aim of study is to compare the efficacy of the
      three current antibiotics for the treatment of SBP in patients with liver cirrhosis.

      The primary hypothesis is that the efficacy of all the antibiotics will not significantly
      different. The expected success rates (infection resolution rates) are 83%, 87%, and 78% for
      cefotaxime, ceftriaxone, and ciprofloxacin. This is non-inferiority trial. The level of
      significance is 5%. The power of this stuy is 80%. Non-inferiority margin is 15%. Therefore
      87 patients for each group are needed.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2007</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Infection resolution rates within 5 days of treatment</measure>
    <time_frame>5 days (120 hours)</time_frame>
    <description>PMN &lt; 250/mm3 from ascitic fluid</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infection resolution rates within 5 days</measure>
    <time_frame>5 days (120 hours)</time_frame>
    <description>PMN &lt; 250/mm3 from ascites</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality &amp; recurrence rates within 1 month</measure>
    <time_frame>1 month</time_frame>
    <description>Mortality</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">261</enrollment>
  <condition>SBP</condition>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Cefotaxime</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>standard treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ceftriaxone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Potential better treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ciprofloxacine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefotaxime</intervention_name>
    <description>3 g</description>
    <arm_group_label>Cefotaxime</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceftriaxone</intervention_name>
    <description>2 g</description>
    <arm_group_label>Ceftriaxone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprofloxacin</intervention_name>
    <description>400 mg</description>
    <arm_group_label>Ciprofloxacine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Liver cirrhosis patients with ascites

          2. Ascitic fluid PMN cell count &gt;250/mm3

          3. Age: 16~70 years old

        Exclusion Criteria:

          1. Allergic to 3rd generation cephalosporin or quinolone

          2. Antibiotics within 2 weeks

          3. Open abdominal surgery within 4 weeks

          4. Evidence of 2ndary peritonitis, intrabdominal hemorrhage, pancreatitis, Tb
             peritonitis, or peritoneal carcinomatosis

          5. HCC with portal vein thrombosis

          6. Pregnant woman

          7. HIV positive
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Soon Ho Um, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Soon Ho Um, Professor</last_name>
    <phone>82-2-920-5019</phone>
    <email>umsh@korea.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hyung Joon Yim, Professor</last_name>
    <phone>82-31-412-6565</phone>
    <email>gudwns21@korea.ac.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Korea University Ansan Hospital</name>
      <address>
        <city>Ansan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyung Joon Yim</last_name>
      <phone>82-3-412-6565</phone>
      <email>gudwns21@medimail.co.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>136705</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Soon Ho Um, Professor</last_name>
      <phone>82-2-920-5019</phone>
      <email>umsh@korea.ac.kr</email>
    </contact>
    <contact_backup>
      <last_name>Yeon Seok Seo, Professor</last_name>
      <phone>82-2-920-6608</phone>
      <email>drseo@korea.ac.kr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 8, 2014</lastchanged_date>
  <firstreceived_date>December 22, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Korea University</investigator_affiliation>
    <investigator_full_name>Soon Ho Um</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>SBP</keyword>
  <keyword>liver cirrhosis</keyword>
  <keyword>antibiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Peritonitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ceftriaxone</mesh_term>
    <mesh_term>Ciprofloxacin</mesh_term>
    <mesh_term>Cefotaxime</mesh_term>
    <mesh_term>Cefoxitin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
